Phone
N/A
Email
Acknowledgement
1 business day
Genzyme, a Sanofi Company
Sanofi
COVID-19 Information

First patient outside U.S. treated in global Kevzara® (sarilumab) clinical trial program for patients with severe COVID-19

  • Phase 2/3 trial initiated in Italy, Spain, Germany, France, Canada and Russia and is enrolling patients immediately
  • Kevzara inhibits IL-6, which may play a role in driving the inflammatory immune response that causes acute respiratory distress syndrome observed in patients with severe COVID-19 infection
  • Sanofi is leading trials outside the U.S., while Regeneron is leading U.S. trials

For more info, go to:  Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19

See also: https://clinicaltrials.gov/ct2/results?cond=COVID+OR+SARS+OR+MERS+OR+CORONAVIRUS&term=sarilumab&strd_s=01%2F01%2F2020&strd_e=&cntry=&state=&city=&dist=&Search=Search&recrs=a&recrs=b&recrs=c&recrs=d&recrs=f&recrs=k

See also Regeneron in the company directory

Sanofi and Translate Bio collaborate to develop novel mRNA vaccine candidate against COVID-19

Stage
Phase 3
Phase 2
Pre-clinical
Company Type
Vaccine
Late Onset Intervention